Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture - Full Text View

Purpose

The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.

Condition	Intervention	Phase
Osteoporosis Hip Fracture	Drug: Zoledronic Acid	Phase III

MedlinePlus related topics:

Fractures Hip Injuries and Disorders Hip Replacement Osteoporosis

Drug Information available for:

Zoledronic acid

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Further study details as provided by Novartis:

Primary Outcome Measures:

Significant reduction in rate of clinical fractures after surgical repair of hip fracture

Secondary Outcome Measures:

Increase in total hip and femoral neck BMDs

Estimated Enrollment:	2127
Study Start Date:	February 2002

Eligibility

Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female ages 50 years or older
Must have a recent hip fracture repair in the past 90 days
Must be able to walk with or without assistive device (for example, using a walker) prior to the hip fracture

Exclusion Criteria:

Current bisphosphonate users such as aredia (pamidronate), didronel (etidronate), fosamax (alendronate), actonel (residronate), skelid (tiludronate)

Other protocol-defined inclusion/exclusion criteria may apply.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00046254

Show 28 Study Locations

Sponsors and Collaborators

Novartis

More Information

Publications indexed to this study:

Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 Nov 1;357(18):1799-809. Epub 2007 Sep 17.

Study ID Numbers:	CZOL446H2310
First Received:	September 24, 2002
Last Updated:	September 24, 2007
ClinicalTrials.gov Identifier:	NCT00046254
Health Authority:	United States: Food and Drug Administration

Keywords provided by Novartis:

hip fracture

recurrent fracture

fracture

bone loss

bisphosphonate

bone mineral density

osteoporosis

zoledronic acid

geriatrics

rehabilitation

elderly

nursing home

orthopedic

Study placed in the following topic categories:

Zoledronic acid

Fractures, Bone

Wounds and Injuries

Osteoporosis

Disorders of Environmental Origin

Bone Diseases, Metabolic

Bone Diseases

Recurrence

Hip Fractures

Femoral Fractures

Diphosphonates

Musculoskeletal Diseases

Leg Injuries

Additional relevant MeSH terms:

Physiological Effects of Drugs

Bone Density Conservation Agents

Hip Injuries

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008

Sponsored by:	Novartis
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT00046254